Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025

Reuters

Oct 19

Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025

Wuhan YZY Biopharma Co. Ltd. has announced that interim data from its Phase II clinical study of M701, a bispecific antibody drug candidate targeting EpCAM and CD3, for the treatment of malignant pleural effusion (MPE) caused by advanced non-small cell lung cancer in China, was presented at the European Society for Medical Oncology (ESMO) Congress 2025. The data was shared in a poster presentation (Poster No.: 1880P) and will be available on the company's website. The company noted that the development and marketing of M701 are not guaranteed, and advised shareholders and potential investors to exercise caution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief on October 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2576733570"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576733570\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576733570?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-19 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576733570","market":"fut","top_or_hot":-1,"title":"Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Wuhan YZY Biopharma Co. Ltd. has announced that interim data from its Phase II clinical study of M701, a bispecific antibody drug candidate targeting EpCAM and CD3, for the treatment of malignant pleural effusion (MPE) caused by advanced non-small cell lung cancer in China, was presented at the European Society for Medical Oncology (ESMO) Congress 2025. The data was shared in a poster presentation (Poster No.: 1880P) and will be available on the company's website. The company noted that the development and marketing of M701 are not guaranteed, and advised shareholders and potential investors to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief on October 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-19 18:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Wuhan YZY Biopharma Co. Ltd. has announced that interim data from its Phase II clinical study of M701, a bispecific antibody drug candidate targeting EpCAM and CD3, for the treatment of malignant pleural effusion (MPE) caused by advanced non-small cell lung cancer in China, was presented at the European Society for Medical Oncology (ESMO) Congress 2025. The data was shared in a poster presentation (Poster No.: 1880P) and will be available on the company's website. The company noted that the development and marketing of M701 are not guaranteed, and advised shareholders and potential investors to exercise caution.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief on October 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251019:nNDL3w08pw:1","article_id":"2576733570","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576733570","pubTimestamp":1760869899,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Wuhan YZY Biopharma Co. Ltd. has announced that interim data from its Phase II clinical study of M701, a bispecific antibody drug candidate targeting EpCAM and CD3, for the treatment of malignant pleural effusion  caused by advanced non-small cell lung cancer in China, was presented at the European Society for Medical Oncology  Congress 2025. The data was shared in a poster presentation  and will be available on the company's website. The company noted that the development and marketing of M701 are not guaranteed, and advised shareholders and potential investors to exercise caution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief on October 19, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02496":"友芝友生物-B"},"translate_title":"武汉亿智生物制药在ESMO 2025上展示M701治疗恶性胸腔积液的II期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02496":0.9},"content_text":"Wuhan YZY Biopharma Presents Phase II M701 Data for Malignant Pleural Effusion at ESMO 2025\n    \n\n        Wuhan YZY Biopharma Co. Ltd. has announced that interim data from its Phase II clinical study of M701, a bispecific antibody drug candidate targeting EpCAM and CD3, for the treatment of malignant pleural effusion (MPE) caused by advanced non-small cell lung cancer in China, was presented at the European Society for Medical Oncology (ESMO) Congress 2025. The data was shared in a poster presentation (Poster No.: 1880P) and will be available on the company's website. The company noted that the development and marketing of M701 are not guaranteed, and advised shareholders and potential investors to exercise caution.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuhan Yzy Biopharma Co. Ltd. published the original content used to generate this news brief on October 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}